Soma Das to Neoplasms
This is a "connection" page, showing publications Soma Das has written about Neoplasms.
Connection Strength
0.349
-
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework. Br J Cancer. 2026 Oct; 135(8):1286-1297.
Score: 0.079
-
Overall cancer risk in people with deleterious germline DDX41 variants. Haematologica. 2025 09 01; 110(9):2076-2090.
Score: 0.071
-
Sequential tumor molecular profiling identifies likely germline variants. Genet Med. 2024 03; 26(3):101037.
Score: 0.066
-
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 11; 35(11):3245-3256.
Score: 0.055
-
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
Score: 0.034
-
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 01; 68(9):3161-8.
Score: 0.022
-
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Oct 10; 25(29):4622-7.
Score: 0.021